Dianthus Therapeutics DNTH Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's accounts receivable?
- Dianthus Therapeutics (DNTH) reported accounts receivable of $1.23M in Q1 2026.
- How has Dianthus Therapeutics's accounts receivable changed year-over-year?
- Dianthus Therapeutics's accounts receivable increased by 23.0% year-over-year, from $1M to $1.23M.
- What is the long-term trend for Dianthus Therapeutics's accounts receivable?
- Over 3 years (2022 to 2025), Dianthus Therapeutics's accounts receivable has grown at a -77.7% compound annual growth rate (CAGR), from $4.7M to $52K.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.